I'm calling it now: the peptide conversation is moving to X

On Tuesday, October 20, Health Secretary Robert F. Kennedy Jr. told Fox News that the administration's objective is a regulated marketplace for peptides, so that what people buy "is what they claim to be," that it is safe, and that the factories are inspected. His answer came in response to a question about a proposed policy change the FDA sent to the White House for review the week before, which could make it easier for pharmacies to compound certain peptides.

Two things are worth being precise about. The peptides under consideration have not been approved by the FDA as safe or effective. And this is a proposal under review, not a rule that has taken effect — nothing changes today for anyone ordering or researching these compounds.

If that access opens up, the safe bet is that telehealth companies pile in. And a lot of what people find when they search for peptide information will start looking suspiciously like a sales pitch.

You search for an answer and get five different companies explaining why the answer to your question is their monthly subscription. Apparently, every road to better health needs a checkout page.

Look at LegitScript. It is a private certification company, and its certification is required for US telehealth providers advertising prescription services on Google and Meta, alongside the platforms' own approvals. That gives it considerable influence over who gets access to paid advertising.

That influence is worth understanding rather than assuming. Google's healthcare policy requires telemedicine providers to be certified through LegitScript's Healthcare Merchant Certification Program, and the platforms still require their own healthcare certification on top. LegitScript's own framing is that certification is the driver's license, not the road rules: it is the entry requirement, and every ad has to clear the platform's rules afterwards.

The part worth watching is how the line between education and promotion gets drawn.

LegitScript says educational content is generally allowed for certified businesses. But content encouraging the use of an unapproved drug can violate its standards even when that business does not sell the product. Those are certification rules, which are separate from the rules governing ordinary Facebook posts.

Here is the concern: combine restrictive advertising access with pharma and telehealth money, and independent voices can get drowned out long before anyone outright bans the conversation. Not by a rule that says you may not discuss this, but by a set of rules that decides who can afford to be seen.

Patient safety matters. So does being able to question the companies, platforms and certification bodies deciding what gets promoted. Saying "patient safety" should not end the discussion about money, incentives and who benefits.

Research-use-only sellers do not get a free pass either. Bullshit is bullshit, whether it comes from a pharmaceutical company, a telehealth brand or someone selling research vials. A certificate does not make a vendor honest, and the absence of one does not make a vendor dishonest. The test is the evidence, not the badge.

What people actually need is room to discuss the research, challenge exaggerated claims and ask uncomfortable questions. Including the questions that do not help anybody sell something.

That is why more of the health, fitness, peptide and biohacking conversation will move to X. People go where there is room to talk without every discussion turning into an approved sales pitch — where a question does not have to clear an advertising review before it can be answered.

Soon we will be calling it Peptide X. As long as X does not sell out.

• Whether the compounding proposal clears review, and what the final rule actually says.
• How telehealth advertising shows up in search results for peptide terms over the next six months.
• Whether certification standards end up applied to education the way they are applied to promotion.
• Where the independent creators go, and whether the conversation follows them.